

Answering the Call: Practical Strategies for Improving Earlier Diagnosis and Patient-Centered Management in Primary Care

Tweetorial #1: Earlier Screening, Diagnosis, & Assessment of COPD References

Tweet 5

Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. *Lancet Respir Med*. 2017;5(5):426-434. doi:10.1016/S2213-2600(17)30119-4

Çolak Y, Afzal S, Nordestgaard BG, Lange P, Vestbo J. Importance of early COPD in young adults for development of clinical COPD. Findings from the Copenhagen General Population Study. *Am J Respir Crit Care Med*. 2021;203(10):1245-1256. doi:10.1164/rccm.202003-0532OC

GOLD. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2022 Report. Global Initiative for Chronic Obstructive Lung Disease; 2022.

Tweet 6

Larsson K, Janson C, Ställberg B, et al. Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study. *Int J Chron Obstruct Pulmon Dis*. 2019;14:995-1008. doi:10.2147/COPD.S195382

Natali D, Cloatre G, Hovette P, Cochrane B. Screening for comorbidities in COPD. *Breathe (Sheff)*. 2020;16(1):190315. doi:10.1183/20734735.0315-2019

Tzovaras NZ, Kouloumenta VN, Gourgoulisanis KI. The economic impact of late detection of COPD in general practice. *Chest*. 2005;127:412; author reply 412-413. doi:10.1378/chest.127.1.412

Tweet 8

Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med*. 2005;142(4):233-239. doi:10.7326/0003-4819-142-4-200502150-00005

Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. *COPD*. 2010;7(5):375-382. doi:10.3109/15412555.2010.510160

Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ*. 2000;320(7425):1297-1303. doi:10.1136/bmj.320.7245.1297

Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. *Respir Med*. 2006;100(1):115-122. doi:10.1016/j.rmed.2005.03.035.

McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, for the TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax*. 2007;62(5):411-415. doi:10.1136/thx.2006.072348

Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 1999;340(25):1948-1953. doi:10.1056/NEJM19990624340250

Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? *Eur Respir Rev*. 2018;27(149):180057. doi:10.1183/16000617.0057-2018

Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med*. 2008;359:1543-1554. doi:10.1016/j.arbres.2012.04.001

Tweet 12

IPCRG Desktop Helper: Early diagnosis of COPD does help! November 17, 2009. Accessed June 1, 2022. <https://www.ipcr.org/dtheearlydiagcopd>

Tweet 14

IPCRG Desktop Helper: Spirometry. March 2010. Accessed June 1, 2022. Available at: [https://www.ipcr.org/sites/ipcr/files/content/attachments/2020-03-04/IPCRG Desktop Helper Spirometry.pdf](https://www.ipcr.org/sites/ipcr/files/content/attachments/2020-03-04/IPCRG_Desktop_Helper_Spirometry.pdf)

Tweet 15

Eschenbache W. Airflow limitation and spirometry. In: Panos RJ, ed. *COPD Clinical Perspectives*. IntechOpen. 2011.

Tweet 17

IPCRG Desktop Helper: Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD). May 2020. Accessed March 2, 2022. <https://www.ipcr.org/sites/ipcr/files/content/attachments/2020-06-02/IPCRG%20DH6%20ICS%20COPD%20Rev%20May20.pdf>

GOLD. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2022 Report. Global Initiative for Chronic Obstructive Lung Disease; 2022.

Miravittles M, Soler-Cataluña SS, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. *Arch Bronconeumol*. 2012;48(7):247-257. doi:10.1016/j.arbres.2012.04.001

Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. an official american thoracic society clinical practice guideline. *Am J Respir Crit Care Med*. 2020;201(9):e56-e69. doi:10.1164/rccm.202003-0625ST

Glossary

A1AT, alpha-1 antitrypsin
AATD, alpha-1 antitrypsin deficiency
AF, atrial fibrillation
ATS, American Thoracic Society
BMI, body mass index
CAT, COPD Assessment Test
CBC, complete blood count
CLHT, Canada Lung Health Test
COPD, chronic obstructive pulmonary disease
CV, cardiovascular
CVD, cardiovascular disease
Dx, diagnosis/diagnostic
FEV, forced expiratory volume
FV, flow volume
FVC, forced vital capacity
GesEPOC, Spanish COPD Guidelines
GOLD, Global Initiative for Chronic Obstructive Lung Disease
HCRT, high-resolution computed tomography
HR, hazard ratio
Hx, history
IPCRG, International Primary Care Respiratory Group
LLN, lower limits of normal
MEF, maximal expiratory flow
MMEF, maximum mid-expiratory flow
mMRC, modified Medical Research Council score
NICE, National Institute for Health and Clinical Excellence
OCS, oral corticosteroids
PEF, peak expiratory flow
PR, pulmonary rehabilitation
pts, patients
Tx, treatment
Y, year
YO, year old
VT, volume-time
w/, with